細(xì)胞名稱(chēng)

人急性髓系白血病細(xì)胞MUTZ-3

貨物編碼

BFN60808560

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細(xì)胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運(yùn)輸方式

常溫保溫運(yùn)輸

干冰運(yùn)輸

安全等級(jí)

1

用途限制

僅供科研      2類(lèi)

培養(yǎng)體系

DMEM高糖+10%FBS+1%三抗

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡(jiǎn)介

人急性髓系白血病細(xì)胞MUTZ-3取自29歲男性病人外周血。該細(xì)胞源于DSMZ。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: LL-100 blood cancer cell line panel.

Characteristics: Contains both CD34+ stem cell and CD14+ monocyte/macrophage cell populations and can thus be considered as a hematopoietic progenitor/stem cell line.

Doubling time: ~110 hours (DSMZ); 90-110 hours, in presence of supernatant of 5637 (CVCL_0126) cells (PubMed=8667638).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: H3K79me1 ChIP-seq epigenome analysis.

Omics: Transcriptome analysis.

Derived from sampling site: Peripheral blood.

基因突變

KRAS p.Gly10_Ala11insGly (c.31_32insGAG) (CCLE).

HLA信息

/

STR信息

Amelogenin        X,Y

CSF1PO        12,13

D5S818        12,13

D7S820        10,12

D13S317        8,12

D16S539        12

TH01        6,9.3

TPOX        8,11

vWA        14,16

參考文獻(xiàn)

Patent=US8455253

Goletz S., Scheper R.J., Masterson A.J., Pinedo H.M.

Differentiation of MUTZ-3 cells to produce effective dendritic cells.

Patent number US8455253, 04-Jun-2013

PubMed=30285677; DOI=10.1186/s12885-018-4840-5

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940-940(2018)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)